Visit Booth: R224A

Laboratoires Horus Pharma

Website address: www.horus-pharma.fr

Company contacts:

NUTRACEUTICAL + DEVICES + DRUGS LABORATORY

Visit Booth: R237

Leica Microsystems

Website address: www.leica-microsystems.com

Company contacts:

Leica Microsystems is a world leader in providing innovative microscopy, camera and software solutions for imaging and analysis of macro, micro and nanostructures.

Visit Booth: R240

LKC Technologies, Inc.

Website address: www.lkc.com

Company contacts: LKC Technologies, Inc.
2 Professional Drive, Suite 222
Gaithersburg, MD 20879
U.S.A.
Phone: 1-301-840-1992
Fax: 1-301-330-2237
Email: sales@lkc.com

RETevalTM is the world's first FDA approved dilated or undilated ISCEV compliant flash ERG/VEP device which uses either LKC Sensor Strip skin electrodes or corneal electrodes. It's easy to use, hand-held, and accurate. See how fast and easy visual electrophysiology can be - Stand #R240.

RETeval-DR, sold by Welch Allyn, is highly sensitive and specific to sight threatening diabetic retinopathy with immediate objective results in less than 3 minutes per patient regardless of pupil size or the presence of cataracts.

The LKC UTAS pattern and flash ERG/MFERG, VEP/MFVEP and EOG system will meet all of your visual electrophysiology needs.

Visit Booth: R215A

Lumenis

Website address: www.lumenis.com

Company contacts:

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Ophthalmology, Surgical and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies.
In Ophthalmology, Lumenis revolutionized the way eye surgery is performed, introducing the first ophthalmic Argon photocoagulator; the first approved marketer of Nd:YAG photodisruptor lasers; developed and introduced the breakthrough technology of multicolor photocoagulation along with the world's first Laser Indirect Ophthalmoscope (LIO).
Lumenis is also the force behind the groundbreaking Selective Laser Trabeculoplasty (SLT) for managing open-angle glaucoma, offering proven clinical efficacy with an impressive 93% success rate!